Saffron Cognitive Performance Randomized Trial: What the Evidence Says

Quick Answer

Saffron Cognitive Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 narrative review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• In recent years, a growing body of scientific evidence supporting several of these traditional uses has shown the potential of saffron and its main ingredients-crocins, crocetin, safranal, and picrocrocin-as pharmacologically relevant compounds. [Campos Catarina (2026); evidence level 3]
• By integrating evidence from in vitro studies, animal models, and clinical trials, this review critically assesses saffron's potential as a multi-target pharmacological agent and identifies key limitations and future directions for its development within pharmaceutical and integrative medicine frameworks. [Campos Catarina (2026); evidence level 3]
• Advances in medicine, technology, and socioeconomic development have extended life expectancy, but these gains are accompanied by a steep rise in age-associated diseases. [Li Lingyun (2025); evidence level 4]
• These conditions are driven by a complex interplay of genetic, molecular, and environmental factors, with aging itself serving as the strongest risk factor. [Li Lingyun (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For saffron cognitive performance randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Campos Catarina (2026). From Stigma to Therapy: Pharmacological Insights into Saffron Bioactives for Major Non-Communicable Diseases. DOI: 10.3390/ph19030484. PMCID: PMC13029429. PMID: 41901329. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13029429/
• Li Lingyun (2025). Integrative effects of saffron and physical activity on endurance performance, quality of life, cognitive, emotional, and metabolic outcomes in age-related and neurodegenerative diseases. DOI: 10.3389/fnut.2025.1698135. PMCID: PMC12695556. PMID: 41393939. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12695556/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.